DIANOSIC

Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The project originates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are... Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing. Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain. Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform.More